{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "53", "lastUpdated": "2024-08-26T11:07:14.436Z"}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "236984", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "109587"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "Health_related_quality_of_lifefrom_MAGICapp_109587", "title": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparativeEvidence", "display": "ComparativeEvidence"}]}}], "relatedArtifact": [{"type": "part-of", "resourceReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "variableDefinition": [{"description": "Adults with type 2 diabetes", "variableRole": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/variable-role", "code": "population", "display": "population"}], "text": "Use extension:variableRoleCode instead."}, "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Adults with type 2 diabetes and CVD and CKD", "reference": "Group/236947"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code", "valueCode": "population"}], "note": [{"text": "population"}]}, {"description": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "variableRole": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/variable-role", "code": "exposure", "display": "exposure"}], "text": "Use extension:variableRoleCode instead."}, "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "reference": "EvidenceVariable/236950"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code", "valueCode": "exposure"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category", "valueString": "GLP-1 RA"}], "note": [{"text": "exposure"}]}, {"description": "Health-related quality of life", "variableRole": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/variable-role", "code": "measuredVariable", "display": "measured variable"}], "text": "Use extension:variableRoleCode instead."}, "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-109587", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Health-related quality of life", "reference": "EvidenceVariable/236983"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code", "valueCode": "outcome"}], "note": [{"text": "outcome"}]}], "synthesisType": {"text": "SYSTEMATIC_REVIEW"}, "studyDesign": [{"text": "NOTSET"}], "statistic": [{"description": "SMD 0.01  (CI95 -0.19  to 0.2 )", "statisticType": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-type", "version": "5.0.0-cibuild", "code": "0000100", "display": "Standardized Mean Difference"}]}, "quantity": {"value": 0.01}, "attributeEstimate": [{"type": {"text": "CI95"}, "range": {"low": {"value": -0.19}, "high": {"value": 0.2}}}]}], "certainty": [{"description": "Due to very serious imprecision", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Overall", "display": "Overall certainty"}]}, "rating": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/27834", "code": "RJCS-2005", "display": "Low certainty"}]}, "subcomponent": [{"type": {"text": "Risk of Bias"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Inconsistency"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Indirectness"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Imprecision"}, "rating": {"text": "VERY_SERIOUS"}}, {"type": {"text": "Publication Bias"}, "rating": {"text": "NOTSET"}}]}], "assertion": "There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.", "url": "https://fevir.net/resources/Evidence/236984", "id": "236984", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}